{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Multiple+Sclerosis+%28MS%29+-+Relapsing-remitting&page=5",
    "query": {
      "condition": "Multiple Sclerosis (MS) - Relapsing-remitting",
      "page": 5
    },
    "page_size": 10
  },
  "pagination": {
    "page": 5,
    "page_size": 10,
    "total_count": 104,
    "total_pages": 11,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Multiple+Sclerosis+%28MS%29+-+Relapsing-remitting&page=6&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Multiple+Sclerosis+%28MS%29+-+Relapsing-remitting&page=4&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-14T03:03:10.703Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01633112",
      "title": "MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Relapsing-remitting Multiple Sclerosis (RRMS)"
      ],
      "interventions": [
        {
          "name": "fingolimod",
          "type": "DRUG"
        },
        {
          "name": "glatiramer acetate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 1064,
      "start_date": "2012-08-09",
      "completion_date": "2018-04-30",
      "has_results": true,
      "last_update_posted_date": "2019-05-28",
      "last_synced_at": "2026-11-14T03:03:10.703Z",
      "location_count": 101,
      "location_summary": "Cullman, Alabama • Phoenix, Arizona • Tucson, Arizona + 88 more",
      "locations": [
        {
          "city": "Cullman",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01633112"
    },
    {
      "nct_id": "NCT01848327",
      "title": "Caprylic Triglyceride for Treatment of Cognitive Impairments in Multiple Sclerosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Relapsing Remitting MS",
        "Secondary Progressive MS",
        "Primary Progressive MS"
      ],
      "interventions": [
        {
          "name": "Caprylic Triglyceride",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Placebo",
          "type": "DIETARY_SUPPLEMENT"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "University of Miami",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "59 Years",
        "sex": "ALL",
        "summary": "18 Years to 59 Years"
      },
      "enrollment_count": 124,
      "start_date": "2013-02",
      "completion_date": "2017-12",
      "has_results": false,
      "last_update_posted_date": "2018-01-25",
      "last_synced_at": "2026-11-14T03:03:10.703Z",
      "location_count": 1,
      "location_summary": "Miami, Florida",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01848327"
    },
    {
      "nct_id": "NCT05925049",
      "title": "A Study Utilising Data From European Union (EU) National Multiple Sclerosis (MS) Registries to Assess the Incidence of Anti-Natalizumab Antibody Among Participants Who Receive Subcutaneous Administration of Natalizumab for Treatment of Relapsing-remitting Multiple Sclerosis (RRMS)",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Multiple Sclerosis"
      ],
      "interventions": [
        {
          "name": "Natalizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Biogen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "64 Years",
        "sex": "ALL",
        "summary": "18 Years to 64 Years"
      },
      "enrollment_count": 271,
      "start_date": "2023-06-30",
      "completion_date": "2026-10-29",
      "has_results": false,
      "last_update_posted_date": "2026-11-12",
      "last_synced_at": "2026-11-14T03:03:10.703Z",
      "location_count": 1,
      "location_summary": "Cambridge, Massachusetts",
      "locations": [
        {
          "city": "Cambridge",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05925049"
    },
    {
      "nct_id": "NCT02290444",
      "title": "Effects of Acthar on Recovery From Cognitive Relapses in MS",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Multiple Sclerosis"
      ],
      "interventions": [
        {
          "name": "Adrenocorticotropic Hormone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "State University of New York at Buffalo",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 64,
      "start_date": "2013-08",
      "completion_date": "2018-11-01",
      "has_results": true,
      "last_update_posted_date": "2020-04-06",
      "last_synced_at": "2026-11-14T03:03:10.703Z",
      "location_count": 1,
      "location_summary": "Buffalo, New York",
      "locations": [
        {
          "city": "Buffalo",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02290444"
    },
    {
      "nct_id": "NCT07222956",
      "title": "A Study of Remibrutinib Using MR Imaging in Relapsing or Progressive MS",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Multiple Sclerosis (MS) - Relapsing-remitting",
        "Multiple Sclerosis (MS) Secondary Progressive",
        "Multiple Sclerosis (MS) Primary Progressive"
      ],
      "interventions": [
        {
          "name": "Remibrutinib (Open Label)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Moein Amin",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 20,
      "start_date": "2027-03-01",
      "completion_date": "2030-12-30",
      "has_results": false,
      "last_update_posted_date": "2026-08-19",
      "last_synced_at": "2026-11-14T03:03:10.703Z",
      "location_count": 1,
      "location_summary": "Cleveland, Ohio",
      "locations": [
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07222956"
    },
    {
      "nct_id": "NCT01116427",
      "title": "A Cooperative Clinical Study of Abatacept in Multiple Sclerosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Multiple Sclerosis, Relapsing-Remitting"
      ],
      "interventions": [
        {
          "name": "abatacept",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 65,
      "start_date": "2010-09",
      "completion_date": "2015-02",
      "has_results": true,
      "last_update_posted_date": "2016-09-15",
      "last_synced_at": "2026-11-14T03:03:10.703Z",
      "location_count": 20,
      "location_summary": "Phonix, Arizona • Berkeley, California • Los Angeles, California + 17 more",
      "locations": [
        {
          "city": "Phonix",
          "state": "Arizona"
        },
        {
          "city": "Berkeley",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01116427"
    },
    {
      "nct_id": "NCT00391352",
      "title": "fMRI Study of Treatment Recommendations Comparing Recently Diagnosed Multiple Sclerosis (MS) Patients to Controls",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Relapsing-Remitting Multiple Sclerosis"
      ],
      "interventions": [
        {
          "name": "IFN-β-1a (Rebif®)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Waukesha Memorial Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 21,
      "start_date": "2008-02",
      "completion_date": "2012-08",
      "has_results": false,
      "last_update_posted_date": "2014-06-04",
      "last_synced_at": "2026-11-14T03:03:10.703Z",
      "location_count": 1,
      "location_summary": "Waukesha, Wisconsin",
      "locations": [
        {
          "city": "Waukesha",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00391352"
    },
    {
      "nct_id": "NCT00211887",
      "title": "Combination Therapy in Patients With Relapsing-Remitting Multiple Sclerosis (MS)CombiRx",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Relapsing Remitting Multiple Sclerosis"
      ],
      "interventions": [
        {
          "name": "Interferon beta 1-a",
          "type": "DRUG"
        },
        {
          "name": "glatiramer acetate",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Fred Lublin",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 1008,
      "start_date": "2005-01",
      "completion_date": "2013-03",
      "has_results": true,
      "last_update_posted_date": "2014-04-03",
      "last_synced_at": "2026-11-14T03:03:10.703Z",
      "location_count": 67,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 55 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Berkeley",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00211887"
    },
    {
      "nct_id": "NCT00986960",
      "title": "Effect of Adrenocorticotropin Injection With Weekly Interferon Beta in Patients With Relapsing Remitting Multiple Sclerosis (MS)",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Multiple Sclerosis"
      ],
      "interventions": [
        {
          "name": "repository corticotropin injection",
          "type": "DRUG"
        },
        {
          "name": "Saline",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University at Buffalo",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 0,
      "start_date": "2009-12",
      "completion_date": "2010-12",
      "has_results": false,
      "last_update_posted_date": "2021-01-05",
      "last_synced_at": "2026-11-14T03:03:10.703Z",
      "location_count": 1,
      "location_summary": "Buffalo, New York",
      "locations": [
        {
          "city": "Buffalo",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00986960"
    },
    {
      "nct_id": "NCT00914758",
      "title": "Comparison of Campath and Rebif Treatment on Cognition in Multiple Sclerosis (MS)",
      "overall_status": "UNKNOWN",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Relapsing Remitting Multiple Sclerosis"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Washington Neuropsychology Research Group",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "25 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "25 Years to 50 Years"
      },
      "enrollment_count": 1,
      "start_date": "2009-03",
      "completion_date": "2011-12",
      "has_results": false,
      "last_update_posted_date": "2009-06-05",
      "last_synced_at": "2026-11-14T03:03:10.703Z",
      "location_count": 7,
      "location_summary": "Berkely, California • Lexington, Kentucky • Springfield, Massachusetts + 4 more",
      "locations": [
        {
          "city": "Berkely",
          "state": "California"
        },
        {
          "city": "Lexington",
          "state": "Kentucky"
        },
        {
          "city": "Springfield",
          "state": "Massachusetts"
        },
        {
          "city": "Lebanon",
          "state": "New Hampshire"
        },
        {
          "city": "Latham",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00914758"
    }
  ]
}